Literature DB >> 15583118

Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes.

Jeffrey H Meyer1, Sylvain Houle, Sandra Sagrati, Anna Carella, Doug F Hussey, Nathalie Ginovart, Verdell Goulding, James Kennedy, Alan A Wilson.   

Abstract

BACKGROUND: Although brain serotonin transporter (5-HTT) density has been investigated in subjects with a history of major depressive episodes (MDE), there has never been an investigation of brain 5-HTT during a current MDE. Brain 5-HTT binding potential (BP) may have an important role during MDE due to major depressive disorder, because the 5-HTT regulates extracellular 5-HT. The BP is an index of receptor density. Carbon 11-labeled 3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile (DASB) positron emission tomography (PET) is the first brain imaging technique that can measure the 5-HTT BP in cortical and subcortical brain regions in vivo. The purposes of this study were to investigate 5-HTT BP during MDE and to determine the relationship between 5-HTT BP and negativistic dysfunctional attitudes during MDE. Dysfunctional attitudes are negatively biased assumptions and beliefs regarding oneself, the world, and the future. Our recent publication of increased serotonin2 BP in MDE with severely negativistic dysfunctional attitudes suggests that this subgroup of MDE subjects has very low levels of extracellular serotonin.
METHODS: Regional 5-HTT BP was measured in 20 nonsmoking medication-free (> or =3 months) depressed subjects and 20 age-matched nonsmoking, medication-free, healthy subjects using [11C]DASB PET. Dysfunctional attitudes were measured using the Dysfunctional Attitudes Scale.
RESULTS: No difference in regional 5-HTT BP was found between MDE and healthy subjects; however, the subgroup of MDE subjects with highly negativistic dysfunctional attitudes had significantly higher 5-HTT BP compared with healthy subjects in brain regions mainly sampling serotonergic nerve terminals (prefrontal cortex, anterior cingulate, thalamus, bilateral caudate, and bilateral putamen; average, 21% greater; F(1,26), 5.6-12.2 [P values, .03-.002]). In the MDE subjects, increased 5-HTT BP was strongly associated with more negativistic dysfunctional attitudes in brain regions primarily sampling serotonergic nerve terminals (prefrontal cortex, anterior cingulate, thalamus, caudate, and putamen; r = 0.64-0.74 [P values, .003 to <.001]).
CONCLUSIONS: Serotonin transporters play an important role during depression. The magnitude of regional 5-HTT BP can provide a vulnerability to low levels of extracellular serotonin and symptoms of extremely negativistic dysfunctional attitudes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15583118     DOI: 10.1001/archpsyc.61.12.1271

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  68 in total

1.  Central serotonin transporter levels are associated with stress hormone response and anxiety.

Authors:  Matthias Reimold; Astrid Knobel; Michael A Rapp; Anil Batra; Klaus Wiedemann; Andreas Ströhle; Anke Zimmer; Peter Schönknecht; Michael N Smolka; Daniel R Weinberger; David Goldman; Hans-Jürgen Machulla; Roland Bares; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2010-06-29       Impact factor: 4.530

2.  Loudness dependence of auditory evoked potentials (LDAEP) correlates with the availability of dopamine transporters and serotonin transporters in healthy volunteers-a two isotopes SPECT study.

Authors:  I Hui Lee; Yen Kuang Yang; Po See Chen; Hui Chun Huang; Tzung Lieh Yeh; Ru-Band Lu; Nan-Tsing Chiu; Wei Jen Yao; Shih-Hsien Lin
Journal:  Psychopharmacology (Berl)       Date:  2010-11-12       Impact factor: 4.530

3.  Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter.

Authors:  Karl Strecker; Florian Wegner; Swen Hesse; Georg-Alexander Becker; Marianne Patt; Philipp M Meyer; Donald Lobsien; Johannes Schwarz; Osama Sabri
Journal:  J Neurol       Date:  2010-07-21       Impact factor: 4.849

4.  Length of axons expressing the serotonin transporter in orbitofrontal cortex is lower with age in depression.

Authors:  Grazyna Rajkowska; Gouri Mahajan; Beata Legutko; Lavanya Challagundla; Michael Griswold; Paul R Albert; Mireille Daigle; Jose J Miguel-Hidalgo; Mark C Austin; Randy D Blakely; David C Steffens; Craig A Stockmeier
Journal:  Neuroscience       Date:  2017-07-13       Impact factor: 3.590

Review 5.  Positron emission tomography molecular imaging in late-life depression.

Authors:  Kentaro Hirao; Gwenn S Smith
Journal:  J Geriatr Psychiatry Neurol       Date:  2014-01-05       Impact factor: 2.680

6.  Biologic effects of mindfulness meditation: growing insights into neurobiologic aspects of the prevention of depression.

Authors:  Simon N Young
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

7.  [123I] ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials.

Authors:  Oliver Pogarell; Walter Koch; Nadine Schaaff; Gabriele Pöpperl; Christoph Mulert; Georg Juckel; Hans-Jürgen Möller; Ulrich Hegerl; Klaus Tatsch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

8.  A PET study on regional coexpression of 5-HT1A receptors and 5-HTT in the human brain.

Authors:  Johan Lundberg; Jacqueline Borg; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2007-09-15       Impact factor: 4.530

9.  Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder.

Authors:  Jeffrey M Miller; Natalie Hesselgrave; R Todd Ogden; Gregory M Sullivan; Maria A Oquendo; J John Mann; Ramin V Parsey
Journal:  Biol Psychiatry       Date:  2013-03-01       Impact factor: 13.382

10.  Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender.

Authors:  Henricus G Ruhé; Jan Booij; Johannes B Reitsma; Aart H Schene
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-30       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.